Stock Scorecard



Stock Summary for Soleno Therapeutics Inc (SLNO) - $54.83 as of 11/20/2024 8:43:19 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SLNO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SLNO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SLNO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SLNO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SLNO (44 out of 90)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0

Latest News for for SLNO

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release ( DCCR ) Tablets in Prader-Willi Syndrome at ESPE 2024 - Soleno Therapeutics ( NASDAQ:SLNO ) 11/14/2024 9:05:00 PM
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA 10/9/2024 1:33:00 PM
Why Soleno Therapeutics Stock Blasted 9% Higher Today 10/8/2024 10:29:00 PM
Soleno Therapeutics's Options Frenzy: What You Need to Know - Soleno Therapeutics ( NASDAQ:SLNO ) 10/8/2024 3:15:00 PM
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday - PepsiCo ( NASDAQ:PEP ) 10/8/2024 2:12:00 PM
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review 8/28/2024 2:25:00 PM
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday - Hain Celestial Group ( NASDAQ:HAIN ) 8/27/2024 2:38:00 PM
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR ( Diazoxide Choline ) Extended-Release Tablets in Prader-Willi Syndrome 8/27/2024 12:00:00 PM
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR ( Diazoxide Choline ) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome 6/28/2024 12:00:00 PM
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 6/24/2024 9:18:00 PM

Financial Details for SLNO

Company Overview

Ticker SLNO
Company Name Soleno Therapeutics Inc
Country USA
Description Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.
Sector Name LIFE SCIENCES
Industry Name ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 54.83
Price 4 Years Ago 28.95
Last Day Price Updated 11/20/2024 8:43:19 PM EST
Last Day Volume 672,975
Average Daily Volume 722,963
52-Week High 59.75
52-Week Low 26.38
Last Price to 52 Week Low 107.85%

Valuation Measures

Trailing PE N/A
Industry PE 46.45
Sector PE 40.32
5-Year Average PE -7.29
Free Cash Flow Ratio 9.20
Industry Free Cash Flow Ratio 20.82
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 17.26
Total Cash Per Share 5.96
Book Value Per Share Most Recent Quarter 6.45
Price to Book Ratio 8.44
Industry Price to Book Ratio 4.06
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 3.24
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 43,117,400
Market Capitalization 2,364,127,042
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -62.00%
Reported EPS 12 Trailing Months -2.79
Reported EPS Past Year -2.99
Reported EPS Prior Year -2.97
Net Income Twelve Trailing Months -131,156,000
Net Income Past Year -38,988,000
Net Income Prior Year -24,067,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 256,776,000
Total Cash Past Year 169,681,000
Total Cash Prior Year 14,602,000
Net Cash Position Most Recent Quarter 256,776,000
Net Cash Position Past Year 169,681,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 157,507,000
Total Stockholder Equity Prior Year 10,348,000
Total Stockholder Equity Most Recent Quarter 264,699,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -51,629,000
Free Cash Flow Per Share Twelve Trailing Months -1.20
Free Cash Flow Past Year -24,940,000
Free Cash Flow Prior Year -20,794,000

Options

Put/Call Ratio 0.67
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.34
MACD Signal 1.42
20-Day Bollinger Lower Band 42.17
20-Day Bollinger Middle Band 50.19
20-Day Bollinger Upper Band 58.22
Beta -1.44
RSI 51.40
50-Day SMA 45.54
150-Day SMA 18.65
200-Day SMA 18.46

System

Modified 11/19/2024 12:50:43 PM EST